AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
Portfolio Pulse from
AstraZeneca and Daiichi Sankyo have withdrawn their regulatory filing for Dato-DXd, a treatment for nonsquamous non-small cell lung cancer, in the European Union.
December 26, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca has withdrawn its EU regulatory filing for Dato-DXd, a treatment for nonsquamous non-small cell lung cancer, which may impact its short-term stock performance.
The withdrawal of a regulatory filing can be seen as a setback for AstraZeneca, potentially affecting investor confidence and leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80